The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Abstract Text:

Robert P Evans,Claudia Naber,Tara Steffler,Tamara Checkland,Christopher A Maxwell,Jonathan J Keats,Andrew R Belch,Linda M Pilarski,Raymond Lai,Tony Reiman,Robert P Evans,Claudia Naber,Tara Steffler,Tamara Checkland,Christopher A Maxwell,Jonathan J Keats,Andrew R Belch,Linda M Pilarski,Raymond Lai,Tony Reiman,

Aurora kinases are potential targets for cancer therapy. Previous studies have validated Aurora kinase A as a therapeutic target in multiple myeloma (MM), and have demonstrated in vitro anti-myeloma effects of small molecule Aurora kinase inhibitors that inhibit both Aurora A and B. This study demonstrated that Aurora B kinase was strongly expressed in myeloma cell lines and primary plasma cells. The selective Aurora B inhibitor AZD1152-induced apoptotic death in myeloma cell lines at nanomolar concentrations, with a cell cycle phenotype consistent with that reported previously for Aurora B inhibition. In some cases, AZD1152 in combination with dexamethasone showed increased anti-myeloma activity compared with the use of either agent alone. AZD1152 was active against sorted CD138(+) BM plasma cells from myeloma patients but also, as expected, was toxic to CD138(-) marrow cells from the same patients. In a murine myeloma xenograft model, AZD1152-inhibited tumour growth at well-tolerated doses and induced cell death in established tumours, with associated mild, transient leucopenia. AZD1152 shows promise in these preclinical studies as a novel treatment for MM.

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Publishing Authors By Initials

RP Evans,C Naber,T Steffler,T Checkland,CA Maxwell,JJ Keats,AR Belch,LM Pilarski,R Lai,T Reiman,RP Evans,C Naber,T Steffler,T Checkland,CA Maxwell,JJ Keats,AR Belch,LM Pilarski,R Lai,T Reiman,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: British journal of haematology

VOLUME: 140

Page Numbers: 295-302

Journal Abbreviation: Br. J. Haematol.

ISSN: 1365-2141

DAY: 10

MONTH: 12

YEAR: 2007

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372544

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

AFFILIATION: Department of Oncology, University of Alberta/Cross Cancer Institute, Edmonton, AB, Canada.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Haematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma Related Publications

• Alzheimer's disease a century later.
• Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells.
• Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
• Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment.
• Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions.
• FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice.
• Immunoglobulin G antibodies of children exposed to microorganisms in a water-damaged school.
• Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment.
• Linking brain imaging and genomics in the study of Alzheimer's disease and aging.
• Primary retroperitoneal neoplasms: CT findings in 90 cases with clinical and pathologic correlation.
• Results of a survey on current surgical smoke control practices.
• Self-efficacy, social support and service integration at medical cannabis facilities in the San Francisco Bay area of California.
• Stabilization of the vertical mode in tokamaks by localized nonaxisymmetric fields.
• The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.